SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis

Conclusions: SFX-01 is efficacious in EAE. In first-in-man and phase II clinical trials for other indications, SFX-01 was found to be well-tolerated. A trial comparing BG-12 and SFX-01 would address whether SFX-01 can offer RRMS patients a better option with respect to efficacy and tolerability.Graphical abstract
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research